Forecast

The analysts' average price target is €118.39 (+1.54%). The median is €123.03 (+5.52%).

Buy
  2
Hold
  12
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Apogee Therapeutics reaches record high at $134.89

    Apogee Therapeutics' stock reached a record high of $134.89, representing a year-to-date gain of 256.92%. InvestingPro notes the stock may appear overvalued at this level and that its fair-value estimate is substantially lower. Apogee has more cash than debt but was unprofitable over the past twelve months. Shareholders approved AbbVie's acquisition, which values the company at $10.9 billion ($135.11 per share) and prompted analyst downgrades and adjusted price targets. » More on de.investing.com


  • Apogee Therapeutics reaches record high at $134.47 ahead of takeover by AbbVie

    Apogee Therapeutics shares rose to an all-time high of $134.47 and show a year-to-date return of around 270% with a market capitalization of $10.08 billion. AbbVie announced an acquisition agreement at $135.11 per share, valuing Apogee at about $10.9 billion, while InvestingPro and RSI indicators point to overvaluation and overbought conditions. After the announcement, Mizuho and UBS downgraded the stock from buy to neutral, while RBC raised its price target to $97; Apogee also closed R&D agreements with Paragon Therapeutics and appointed new directors. » More on de.investing.com


  • Apogee Therapeutics sold by Baron Capital after AbbVie agrees $135.11-per-share buyout

    Baron Health Care Fund sold its position in Apogee Therapeutics following AbbVie's announced acquisition of Apogee for $135.11 per share, a 49.5% premium to the prior close. The fund cited Apogee as a key contributor to its biotechnology stock selection during Q2 and reported overall quarterly gains. Apogee shares have risen sharply over the past year and the deal values the company at roughly $10.11 billion. » More on finance.yahoo.com


  • Apogee Therapeutics reaches record high of $134.34

    Shares of Apogee Therapeutics rose to an all-time high of $134.34, about 243% above last year; market capitalization is roughly $10.05 billion. AbbVie announced a takeover agreement at $135.11 per share, valuing the company at about $10.9 billion, after which analysts at Mizuho and UBS downgraded the stock to "Neutral" and cited price targets around $135. Additional developments: a partnership with Paragon Therapeutics to develop an IL-31R antibody, an RBC price target of $97, and the move of zumilokibart into phase III trials. » More on de.investing.com


  • Apogee Therapeutics reaches record high of $133.88 after takeover agreement with AbbVie

    Apogee Therapeutics' stock rose to a record high of $133.88, bringing market capitalization to about $10.02 billion. InvestingPro rates the stock as overvalued versus its fair value and notes an overbought RSI, despite strong performance (+250% over the past year). AbbVie announced a definitive takeover agreement at $135.11 per share (around $10.9 billion), after which several analysts downgraded their ratings to neutral and set price targets near $135. Additionally, Apogee announced collaboration agreements with Paragon Therapeutics to develop antibodies against the interleukin-31 receptor, and confirmed board elections and approved shareholder proposals. » More on de.investing.com

Financials

In the last quarter, Apogee Therapeutics had revenue of €0 and net profit of -€75.23m

(EUR) June 2026
YoY
Revenue 0 -
Gross profit 0 -
Net profit -75.23m 34.15%
EBITDA -73.42m 31.86%

Fundamentals

Metric Value
Market capitalization
€7.66bn
Number of shares
62.2m
52-week high/low
€123.11 - €32.25
Dividends No
Beta
0.34
P/E ratio
-31.12
PEG ratio
6.57
P/B ratio
8.53
P/S ratio
0.00

Company profile

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Name
Apogee Therapeutics
CEO
Michael Thomas Henderson
Headquarters Waltham, ma
USA
Website
Industry
Food Products
IPO
14/07/2023
Employees 261

Ticker symbols

Exchange Symbol
NASDAQ
APGE
🍪

Parqet  uses cookies. Learn more